ORGS
Orgenesis Inc.
$0.5000
0.00%
No data for this timeframe.
Vol
Inst. Holders1 funds
Inst. Value$21.2K
Inst. Activity0 buys / 1 sells
Recent Activity
Inst.
UBS Group AG — EXIT
0 shares ($0.00)
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 14, 2023 | Benchmark | REITERATE | Speculative Buy → Speculative Buy |
| Mar 22, 2023 | Benchmark | REITERATE | Buy |
| Sep 26, 2019 | Benchmark | INITIATE | Speculative Buy |
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| UBS Group AG | $21.2K | EXIT |
1 institutional holders with $21.2K total value (4,743 shares) as of 2024-Q3. Top holders: UBS.
Top Institutional Holders — 2024-Q3
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | UBS Group AG | 4,743 | $21.2K | 100.0% | EXIT -100.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| UBS Group AG | EXIT | 4,743 | 0 | -100.0% | $0.00 | 2024-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Jun 2023): 86% buy across 7 analysts — 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q 2024-03-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2023-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 14, 2023 | Benchmark | REITERATE | Speculative Buy | Speculative Buy |
| Mar 22, 2023 | Benchmark | REITERATE | — | Buy |
| Sep 26, 2019 | Benchmark | INITIATE | — | Speculative Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Apr 1, 2024 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2024 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2024 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2024 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.